The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Coronary interventions

The year in review: coronary interventions

EuroIntervention 2020;15:1534-1547. DOI: 10.4244/EIJ-D-19-01124

1. Department of Cardiology. Xijing hospital, Xi’an, China; 2. Department of Cardiology, Radboud University, Nijmegen, the Netherlands; 3. Department of Cardiology, National University of Ireland Galway, Galway, Ireland; 4. Department of Cardiology, Amsterdam University Medical Center, Amsterdam, the Netherlands; 5. Erasmus Medical Center, Erasmus University, Rotterdam, the Netherlands; 6. Department of Internal Medicine. Cardiology division. University of Campinas (UNICAMP), Campinas, SP, Brazil; 7. Division of Cardiology, Ferrarotto Hospital, University of Catania, Catania, Italy; 8. Deutsches Herzzentrum München, Technische Universität München, Munich, Germany; 9. NHLI, Imperial College London, London, United Kingdom, United Kingdom


Antiplatelet therapy was first introduced almost 30 years ago and remains the cornerstone of percutaneous coronary interventions (PCI). During 2019, the results of several pivotal trials seemed to herald a new era of antiplatelet therapy – the era of the aspirin-free strategy. Also in 2019, the debates on the optimal revascularisation strategy for patients with left main or multivessel disease were reignited, attempting to reduce microvascular obstruction after coronary reperfusion by early infusion of alteplase was disproven, and the result of the ISCHEMIA trial showed no advantage of routine invasive treatment in patients with chronic coronary syndrome (CCS).

New ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
Percutaneous left atrial appendage closure versus non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation and high bleeding risk